HC Wainwright & Co. Maintains Neutral on Co-Diagnostics, Lowers Price Target to $2
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Yi Chen maintains a Neutral rating on Co-Diagnostics (CODX) and lowers the price target from $2.5 to $2.
May 13, 2024 | 11:06 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
HC Wainwright & Co. has maintained a Neutral rating on Co-Diagnostics but reduced the price target from $2.5 to $2, indicating a cautious outlook on the stock's short-term price movement.
The reduction in price target by a reputable analyst firm like HC Wainwright & Co. can lead to negative investor sentiment and potentially lower stock prices in the short term. The maintenance of a Neutral rating suggests that the firm does not see significant upside or downside from the current price level, but the lowering of the price target indicates a more cautious view on the stock's value.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100